Product Overview
Genestra Bio Folic Acid + B12 Liquid- 1 fl oz (30 ml)
• Folic acid and Vitamin B12 in a convenient cherry-flavored liquid format • Helps reduce the risk of neural tube defects when taken daily prior to becoming pregnant and during early pregnancy. A factor in red blood cell formation (1) • Ideal for vegans • Convenient liquid format increases patient compliance
Bio Folic Acid + B12 Liquid is a great-tasting natural cherry-flavored synergistic combination of these two essential nutrients. Bio Folic Acid + B12 Liquid is excellent for children and adults who have difficulty swallowing pills, for vegans. Helps reduce the risk of neural tube defects when taken daily prior to becoming pregnant and during early pregnancy. A factor in the maintenance of good health and red blood cell formation. Helps the body to metabolize carbohydrates, fats and proteins (2).
Additional product info: Micronutrient deficiencies have been associated with significantly high reproductive risks, ranging from infertility to fetal structural defects and long-term diseases. There is consistent scientific evidence that folic acid is of critical importance both pre- and periconceptionally in protecting against Neural Tube Defects (NTDs) in the developing fetus. In general, women are advised to take 0.4 mg/day when planning a pregnancy whereas they are recommended to take 4.0 mg/day if they experienced a previous pregnancy affected by NTD (3). The B vitamins folate, vitamin B6 (pyridoxine), and vitamin B12 (cobalamin) are important regulators of homocysteine metabolism in the body, and randomized controlled trials have demonstrated that supplementation with folate at doses up to 500 µg daily alone or in combination with vitamins B6 and B12 significantly reduces blood homocysteine concentrations (4). Epidemiological evidence suggests that total plasma homocysteine level is an independent cardiovascular risk factor and may have a potential role with regard to outcome after coronary interventions. Studies on the pathogenesis of homocysteine-induced vascular damage have suggested adverse interaction with vascular smooth muscle cells, endothelium function, plasma lipoproteins, and coagulation cascade. A study provides evidence that homocysteine-lowering therapy with folic acid (1 mg/d), vitamin B12 (cyanocobalamin, 400 ?g/d), and vitamin B6 (pyridoxine hydrochloride, 10 mg/d) for 6 months improves outcome after percutaneous coronary intervention (5). In a large cohort of male Finnish smokers, a high dietary folate intake was associated with a significantly lower risk of cerebral infarction (6).
Elderly individuals are susceptible to neurodegenerative diseases that are characterized by cognitive and emotional dysfunction, and severe cortical and subcortical deterioration. Previous studies have reported that high concentrations of homocysteine and lower concentrations of vitamin B6, B12, and folate increase the risk for cognitive decline and pathology in aging populations. Using an optimized voxel-based morphometry (VBM) method and global gray and white matter volume after correcting for age, sex, body mass index, calorie intake, and education, a study showed that adults with greater vitamin B6 (27 mg total) intake had greater gray matter volume along the medial wall, anterior cingulate cortex, medial parietal cortex, middle temporal gyrus, and superior frontal gyrus, whereas people with greater B12 (63.2 µg total) intake had greater volume in the left and right superior parietal sulcus. This study provides intriguing results for the use of B vitamin intake on brain volume and adds to a growing literature on the inverse relationship between vitamin B6, B12, and folate (1927 µg total) on tHcy levels and the risks and effects of tHcy and vitamin intake on cognition and the brain in both pathological and non-pathological aging populations (7).
